Get started
Author

Cristina Martín-Lorente

Observed names: C. Martin-Lorente, C. Martín-Lorente, Cristina Martin-Lorente
OpenAlex ID: A5048868525
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
2022 · Francisco Rodríguez, Pablo Caruana, et al. · Biomolecules · 274
PDF
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
2022 · S.I. Labidi-Galy, M. Rodrigues, et al. · Annals of Oncology · 72
SEOM clinical guideline in ovarian cancer (2020)
2021 · A. Redondo, E. Guerra, et al. · Clinical & Translational Oncology · 47
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
2022 · K.E. Francis, S.I. Kim, et al. · Annals of Oncology · 29
PDF
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
2021 · Eric Pujade-Lauraine, Jessica Brown, et al. · Gynecologic Oncology · 22
SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023)
2024 · Jose Alejandro Perez-Fidalgo, Fernando Gálvez-Montosa, et al. · Clinical & Translational Oncology · 16
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.
2014 · Stephanie Lheureux, Marcus O. Butler, et al. · Journal of Clinical Oncology · 16
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
2022 · Sana Intidhar Labidi-Galy, Manuel Rodrigues, et al. · Journal of Clinical Oncology · 5
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
2021 · Andres Redondo, Ana Oaknin, et al. · Journal of Ovarian Research · 5
A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
2015 · Stephanie Lheureux, Johanne Ingrid Weberpals, et al. · Journal of Clinical Oncology · 5
An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)
2025 · Alejandro Gallego, Ainhoa Madariaga, et al. · International Journal of Gynecological Cancer · 3
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021
2024 · Jose C. Tapia, Freya Bosma, et al. · Clinical Genitourinary Cancer · 3
A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia
2014 · S. Lheureux, M.O. Butler, et al. · Annals of Oncology · 3
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
2026 · Lucy Haggstrom, Yeh Chen Lee, et al. · JAMA Oncology · 2
PDF
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.
2014 · Cristina Martin-Lorente, David SP Tan, et al. · Journal of Clinical Oncology · 2
#869 Niraparib maintenance therapy in patients aged 75 years and older with platinum-sensitive recurrent ovarian cancer: a subgroup assessment of the GEICO-88R study
2023 · Juan Cueva, Yolanda García, et al. · International Journal of Gynecological Cancer · 1
PDF
674 Niraparib as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a GEICO study within the Spanish extended access program
2021 · J.F. Cueva Bañuelos, I. Palacio, et al. · International Journal of Gynecological Cancer · 1
PDF
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
2014 · Michelle Wilson, Neesha C. Dhani, et al. · Journal of Clinical Oncology · 1
452 Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
2024 · Alejandro Gallego, Ainhoa Madariaga, et al. · International Journal of Gynecological Cancer
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis
2024 · Jose C. Tapia, Javier Gavira, et al. · Clinical & Translational Oncology
P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.
2016 · Victoria Mandilaras, Swati Garg, et al. · Journal of Clinical Oncology
Comparative benchmarking of regulatory drug approvals by Food & Drug Administration (FDA): A cross disease comparison with gynecologic malignancies.
2015 · Victor Rodriguez-Freixinos, Michelle K. Wilson, et al. · Journal of Clinical Oncology
Molecular profiling and targeted therapy in advanced endometrial cancer.
2015 · Michelle K. Wilson, Philippe L. Bedard, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 507
H-index: 7
I10-index: 7
Year
Topic
Type